FDA Approved: OPSYNVI — Original Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA approved OPSYNVI, a fixed-dose combination of macitentan and tadalafil, under Original Application NDA218490 for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• OPSYNVI (MACITENTAN AND TADALAFIL)
• TADALAFIL (TADALAFIL)

Snippet

ORIG AP for OPSYNVI (MACITENTAN AND TADALAFIL)